Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIVAS-IgG: IVIg for Protective Immunity Against Strep A Pharyngitis
NCT07864350Phase 1Not yet recruiting
- Sponsor
- Murdoch Children's Research Institute
- Start
- Oct 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial in streptococcal pharyngitis comparing Passive immunisation (intravenous immunoglobulin) with Passive immunisation (saline placebo) (2 arms). Primary endpoint: Proportion of participants who reach the study acute symptomatic pharyngitis endpoint at 5 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
streptococcal pharyngitis
Beyond the preview
Go deeper on NCT07864350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07864350.